Dbv Technologies Advances Peanut Allergy Treatment with New Phase 3 Study

Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.

Dbv Technologies SA is conducting a Phase 3 clinical study titled ‘A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy.’ The study aims to evaluate the 6-month safety of the DBV712 250 mcg patch in young children with peanut allergies, a significant step in addressing this common and potentially severe condition.

The intervention being tested is the DBV712 250 mcg epicutaneous patch, designed to deliver immunotherapy through the skin. This treatment is intended to reduce allergic reactions in children with peanut allergies.

The study is interventional, with participants randomly allocated to either the treatment or placebo group in a parallel model. It employs triple masking, meaning that the participant, care provider, and investigator are unaware of the group assignments. The primary purpose of this study is treatment-focused.

The study began on June 24, 2025, with primary completion expected after the 6-month treatment period. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipated results.

This study update could positively impact Dbv Technologies’ stock performance by demonstrating progress in a promising treatment area. Success in this trial may enhance investor confidence and position the company favorably against competitors in the allergy treatment market.

The study is currently recruiting, with further details available on the ClinicalTrials portal.